| scholarly article | Q13442814 |
| P50 | author | Daniel J. Drucker | Q19966099 |
| P2093 | author name string | Laurie L Baggio | |
| R Mark Henkelman | |||
| Yu-Qing Zhou | |||
| Kiwon Ban | |||
| M Abdul Momen | |||
| Mansoor Husain | |||
| Al-Muktafi Sadi | |||
| Ali M Riazi | |||
| Mohammad Hossein Noyan-Ashraf | |||
| P2860 | cites work | Glucagon-like peptide-1 receptor is involved in learning and neuroprotection | Q28202403 |
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 | ||
| Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis | Q28570314 | ||
| Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons | Q28571689 | ||
| Regulation of cardiac hypertrophy by intracellular signalling pathways | Q29615166 | ||
| Simultaneous evaluation of infarct size and cardiac function in intact mice by contrast-enhanced cardiac magnetic resonance imaging reveals contractile dysfunction in noninfarcted regions early after myocardial infarction | Q30432987 | ||
| The preconditioning phenomenon: A tool for the scientist or a clinical reality? | Q34048255 | ||
| Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore | Q34327908 | ||
| Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart | Q36151679 | ||
| Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction | Q36370540 | ||
| Glucagon-like peptide 1: continued advances, new targets and expanding promise as a model therapeutic | Q36973042 | ||
| New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond | Q37069916 | ||
| Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. | Q40657491 | ||
| Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways | Q42165735 | ||
| Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. | Q43349026 | ||
| Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes | Q43726354 | ||
| Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase--dependent pathway is cardioprotective | Q43909380 | ||
| Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium | Q44512663 | ||
| Elafin-overexpressing mice have improved cardiac function after myocardial infarction | Q44704940 | ||
| Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion | Q44774818 | ||
| One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. | Q44865459 | ||
| Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy | Q45020436 | ||
| Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury | Q45199143 | ||
| Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy | Q46604606 | ||
| Dietary approaches to positively influence fetal determinants of adult health | Q46851302 | ||
| Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts | Q46952887 | ||
| Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes | Q47296454 | ||
| Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes | Q48014037 | ||
| Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure | Q62383757 | ||
| In vivo survival and function of transplanted rat cardiomyocytes | Q70934703 | ||
| Regulation of bcl-2 family proteins during development and in response to oxidative stress in cardiac myocytes: association with changes in mitochondrial membrane potential | Q73175884 | ||
| Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats | Q73195050 | ||
| Tumor necrosis factor-alpha induces apoptosis via inducible nitric oxide synthase in neonatal mouse cardiomyocytes | Q73573637 | ||
| Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice | Q74236314 | ||
| Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure | Q79437872 | ||
| Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state | Q79923829 | ||
| Comprehensive transthoracic cardiac imaging in mice using ultrasound biomicroscopy with anatomical confirmation by magnetic resonance imaging | Q80007972 | ||
| Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway | Q80414128 | ||
| Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines | Q80542636 | ||
| Age-related differences in postinfarct left ventricular rupture and remodeling | Q80669914 | ||
| Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart | Q81538720 | ||
| Abnormal cardiac inflow patterns during postnatal development in a mouse model of Holt-Oram syndrome | Q81681212 | ||
| Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model | Q81730896 | ||
| Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function | Q95821951 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| liraglutide | Q2526479 | ||
| P304 | page(s) | 975-983 | |
| P577 | publication date | 2009-01-16 | |
| P1433 | published in | Diabetes | Q895262 |
| P1476 | title | GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice | |
| P478 | volume | 58 |
| Q42865106 | 3rd Annual Symposium on Self Monitoring of Blood Glucose (SMBG) Applications and Beyond, May 7–8, 2010, London, UK |
| Q39266481 | A New Treatment Strategy for Parkinson's Disease Through the Gut-Brain Axis: The Glucagon-like Peptide-1 Receptor Pathway |
| Q51786227 | A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway. |
| Q42996825 | A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells |
| Q36090588 | A meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure. |
| Q30437335 | A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study) |
| Q38802810 | A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. |
| Q41498937 | A systematic review and meta-analysis of the protective effects of metformin in experimental myocardial infarction |
| Q38698086 | AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation. |
| Q64251759 | AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases |
| Q93540262 | Abstracts of the Plenary and Symposia Talks; and Poster Presentations |
| Q36094441 | Activation of Nrf2 contributes to the protective effect of Exendin-4 against angiotensin II-induced vascular smooth muscle cell senescence |
| Q39754261 | Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol. |
| Q38826068 | After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? |
| Q28740948 | Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency |
| Q55066172 | An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury. |
| Q39600857 | Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes |
| Q85952540 | Balancing benefits and risks in patients receiving incretin-based therapies: focus on cardiovascular and pancreatic side effects |
| Q46164104 | Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial |
| Q38073629 | Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetes |
| Q37677036 | Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus |
| Q43063701 | Blood glucose control and coronary heart disease. |
| Q46637270 | Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials |
| Q35210037 | Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits |
| Q37161933 | Cardiometabolic interventions - focus on transcriptional regulators |
| Q35670896 | Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart |
| Q27303840 | Cardioprotective Signature of Short-Term Caloric Restriction |
| Q38002006 | Cardioprotective effects of incretin during ischaemia-reperfusion |
| Q34640125 | Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies |
| Q37611715 | Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies |
| Q33993725 | Cardiovascular and hemodynamic effects of glucagon-like peptide-1. |
| Q36484283 | Cardiovascular biology of the incretin system |
| Q37023878 | Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials |
| Q26866958 | Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies |
| Q97884553 | Cardiovascular effects of antiobesity drugs: are the new medicines all the same? |
| Q37977336 | Cardiovascular effects of incretin-based therapies |
| Q64917348 | Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. |
| Q90312782 | Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes |
| Q37492640 | Combined MSC and GLP-1 Therapy Modulates Collagen Remodeling and Apoptosis following Myocardial Infarction |
| Q89920670 | Comparative Study of the Effects of GLP1 Analog and SGLT2 Inhibitor against Diabetic Cardiomyopathy in Type 2 Diabetic Rats: Possible Underlying Mechanisms |
| Q51702145 | Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes. |
| Q54945960 | Current Trends in Biomaterial Utilization for Cardiopulmonary System Regeneration. |
| Q84596471 | Current literature in diabetes |
| Q36639293 | DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid |
| Q34566411 | DPP4 deficiency exerts protective effect against H2O2 induced oxidative stress in isolated cardiomyocytes |
| Q28538591 | DPP4 deficiency preserved cardiac function in abdominal aortic banding rats |
| Q84543059 | DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion |
| Q54319337 | Deciphering ventricular GLP-1 action: time for a change of heart. |
| Q35174285 | Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study |
| Q33949425 | Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies |
| Q34716791 | Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies |
| Q36689230 | Diabetes, perioperative ischaemia and volatile anaesthetics: consequences of derangements in myocardial substrate metabolism. |
| Q34690495 | Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney |
| Q37274296 | Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. |
| Q38118157 | Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system |
| Q87690397 | Dipeptidyl peptidase-4 inhibitors are associated with improved left ventricular diastolic function after acute myocardial infarction in diabetic patients |
| Q38132470 | Direct cardiovascular effects of glucagon like peptide-1. |
| Q47333882 | Discovery, characterization, and clinical development of the glucagon-like peptides |
| Q36336983 | Distal coronary embolization following acute myocardial infarction increases early infarct size and late left ventricular wall thinning in a porcine model. |
| Q34041974 | Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia |
| Q37402790 | Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies. |
| Q48059966 | Effect of Liraglutide on Corneal Kindling Epilepsy Induced Depression and Cognitive Impairment in Mice |
| Q36868364 | Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease. |
| Q35532329 | Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study |
| Q35909469 | Effects of Incretin-Based Therapies on Neuro-Cardiovascular Dynamic Changes Induced by High Fat Diet in Rats |
| Q35666901 | Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled trial |
| Q35227453 | Effects of glucagon-like peptide-1 agents on left ventricular function: systematic review and meta-analysis |
| Q37951097 | Effects of incretins on blood pressure: a promising therapy for type 2 diabetes mellitus with hypertension |
| Q50886415 | Effects of liraglutide and ischemic postconditioning on myocardial salvage after I/R injury in pigs. |
| Q41781061 | Effects of liraglutide on hemodynamic parameters in patients with heart failure |
| Q86708661 | Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction |
| Q43019863 | Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus. |
| Q33939256 | Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease |
| Q37395298 | Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? |
| Q40880693 | Encapsulated glucagon-like peptide-1-producing mesenchymal stem cells have a beneficial effect on failing pig hearts |
| Q33631733 | Epac is required for GLP-1R-mediated inhibition of oxidative stress and apoptosis in cardiomyocytes |
| Q40889860 | Essay for the 2011 CIHR/CMAJ award: glucagon-like peptides for metabolic and gastrointestinal disorders |
| Q91737987 | Essential Role Of High Glucose-Induced Overexpression Of PKCβ And PKCδ In GLP-1 Resistance In Rodent Cardiomyocytes |
| Q39590590 | Essential roles of the nitric oxide (no)/cGMP/protein kinase G type-Iα (PKG-Iα) signaling pathway and the atrial natriuretic peptide (ANP)/cGMP/PKG-Iα autocrine loop in promoting proliferation and cell survival of OP9 bone marrow stromal cells |
| Q36694694 | Exenatide Reduces Tumor Necrosis Factor-α-induced Apoptosis in Cardiomyocytes by Alleviating Mitochondrial Dysfunction |
| Q45954775 | Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium. |
| Q35654205 | Exenatide exerts a potent antiinflammatory effect |
| Q41852482 | Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3. |
| Q41878782 | Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages |
| Q44660682 | Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a |
| Q39436443 | Exendin-4 attenuates lipopolysaccharides induced inflammatory response but does not protects H9c2 cells from apoptosis |
| Q34603269 | Exendin-4 improves cardiac function in mice overexpressing monocyte chemoattractant protein-1 in cardiomyocytes. |
| Q98778907 | Exendin-4 inhibits atrial arrhythmogenesis in a model of myocardial infarction-induced heart failure via the GLP-1 receptor signaling pathway |
| Q35132702 | Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix |
| Q47214520 | Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus |
| Q38194069 | Extra-pancreatic effects of incretin-based therapies |
| Q38065321 | Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes |
| Q90051591 | GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats |
| Q33609502 | GIP and GLP-1, the two incretin hormones: Similarities and differences |
| Q41387277 | GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells |
| Q27024984 | GLP-1 and cardioprotection: from bench to bedside |
| Q34727731 | GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. |
| Q34336097 | GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure |
| Q38040314 | GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus |
| Q36406821 | GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. |
| Q38002008 | GLP-1 receptor agonists: a clinical perspective on cardiovascular effects |
| Q38122396 | GLP-1 receptor agonists: effects on cardiovascular risk reduction |
| Q49999597 | GLP-1 receptor expression within the human heart |
| Q45568816 | GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats. |
| Q43105364 | GLP-1(28-36)amide, a Long Ignored Peptide Revisited |
| Q42933615 | GLP-1-based therapy for diabetes: what you do not know can hurt you. |
| Q36209853 | GLP1 protects cardiomyocytes from palmitate-induced apoptosis via Akt/GSK3b/b-catenin pathway |
| Q33750640 | Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice |
| Q35925169 | Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet |
| Q38797077 | Glucagon-Like Peptide 1 Receptor Activation Augments Cardiac Output and Improves Cardiac Efficiency in Obese Swine After Myocardial Infarction |
| Q37777868 | Glucagon-Like Peptide 1—A Cardiologic Dimension |
| Q28067465 | Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes |
| Q52586384 | Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway. |
| Q41267217 | Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure |
| Q37108395 | Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies |
| Q42594418 | Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway |
| Q50958782 | Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. |
| Q51009649 | Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation |
| Q28079849 | Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies |
| Q28070416 | Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome |
| Q36422653 | Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP. |
| Q30039774 | Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells |
| Q36853698 | Glucagon-like peptide-1 triggers protective pathways in pancreatic beta-cells exposed to glycated serum |
| Q37825946 | Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. |
| Q52673331 | Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions. |
| Q33603384 | Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas |
| Q92106443 | Gut Peptide Agonism in the Treatment of Obesity and Diabetes |
| Q49218095 | Gut hormone polyagonists for the treatment of type 2 diabetes |
| Q28081671 | Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide |
| Q90217958 | Identification of expression and function of the glucagon-like peptide-1 receptor in colonic smooth muscle |
| Q38218639 | Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited |
| Q38524435 | Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes |
| Q58466037 | Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide |
| Q42736812 | Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection |
| Q37921901 | Incretin effect: GLP-1, GIP, DPP4. |
| Q26765470 | Incretin-Based Therapy for Prevention of Diabetic Vascular Complications |
| Q37894864 | Incretin-based therapies |
| Q33602360 | Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits |
| Q42578569 | Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus |
| Q38260853 | Incretin-related drug therapy in heart failure |
| Q37082698 | Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering |
| Q35936441 | Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats. |
| Q39778606 | Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. |
| Q49630529 | Is it time to reassess the role of myocardial metabolic modulation for the treatment of heart failure? |
| Q33880174 | Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis |
| Q33486125 | Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model |
| Q58466005 | Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients - a randomized placebo-controlled trial |
| Q33785308 | Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. |
| Q93164933 | Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System |
| Q53723158 | Liraglutide ameliorates cardiotoxicity induced by doxorubicin in rats through the Akt/GSK-3β signaling pathway. |
| Q91790016 | Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways |
| Q35082511 | Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways |
| Q46884095 | Liraglutide attenuates partial warm ischemia-reperfusion injury in rat livers |
| Q37627628 | Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study |
| Q37670940 | Liraglutide directly protects cardiomyocytes against reperfusion injury possibly via modulation of intracellular calcium homeostasis. |
| Q39199887 | Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure |
| Q37470522 | Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. |
| Q64097738 | Liraglutide, a glucagon-like peptide-1 analog, inhibits high glucose-induced oxidative stress and apoptosis in neonatal rat cardiomyocytes |
| Q42406502 | Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage |
| Q37876276 | Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus |
| Q43234814 | Liraglutide: a once-daily human glucagon-like peptide-1 analogue |
| Q37956408 | Liraglutide: a review of its use in the management of type 2 diabetes mellitus |
| Q37595490 | Liraglutide: a review of its use in type 2 diabetes mellitus |
| Q37933408 | Liraglutide: clinical pharmacology and considerations for therapy |
| Q57406244 | Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature |
| Q36800422 | Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling |
| Q34627493 | Mitigation of autophagy ameliorates hepatocellular damage following ischemia-reperfusion injury in murine steatotic liver |
| Q30580723 | Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction |
| Q57818654 | Modulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1) |
| Q89052824 | Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA |
| Q53337186 | Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis. |
| Q88437125 | Molecular and clinical roles of incretin-based drugs in patients with heart failure |
| Q37828337 | Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies |
| Q35821654 | Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart |
| Q48061475 | Neurochemical modulation involved in the beneficial effect of liraglutide, GLP-1 agonist on PTZ kindling epilepsy-induced comorbidities in mice |
| Q39083326 | Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress |
| Q26777654 | New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders |
| Q37992259 | Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide |
| Q34785887 | PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction |
| Q37993945 | Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus |
| Q47275749 | Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes |
| Q59812434 | Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function |
| Q28076059 | Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association |
| Q34062829 | Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system |
| Q37990619 | Potential cardiovascular effects of incretin-based therapies |
| Q26829634 | Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure |
| Q33521451 | Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists |
| Q93140625 | Preliminary evaluation of 18F‑AlF‑NOTA‑MAL‑Cys40‑Exendin‑4 in rodent heart after myocardial ischemia and reperfusion |
| Q33771334 | Prognostic value of plasma DPP4 activity in ST-elevation myocardial infarction |
| Q28081569 | Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials |
| Q42576974 | Regulation of adipocyte formation by GLP-1/GLP-1R signaling |
| Q42040756 | Selective disruption of Tcf7l2 in the pancreatic β cell impairs secretory function and lowers β cell mass. |
| Q34994502 | Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes |
| Q64964866 | Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction. |
| Q93083129 | Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS |
| Q48043450 | Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking |
| Q28535415 | Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms |
| Q41018640 | Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction |
| Q37457580 | Taking diabetes to heart--deregulation of myocardial lipid metabolism in diabetic cardiomyopathy |
| Q36220047 | The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy |
| Q64118590 | The Discovery and Development of Liraglutide and Semaglutide |
| Q40602457 | The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma |
| Q64922464 | The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways. |
| Q50205101 | The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype |
| Q64964485 | The Glp-1 Analog Liraglutide Protects Against Angiotensin II and Pressure Overload-Induced Cardiac Hypertrophy via PI3K/Akt1 and AMPKa Signaling. |
| Q92104984 | The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes |
| Q35041308 | The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study |
| Q36368998 | The cardiovascular effects of GLP-1 receptor agonists |
| Q38134902 | The cardiovascular safety of incretin-based therapies: a review of the evidence |
| Q37980019 | The effect of glucagon-like peptide 1 on cardiovascular risk |
| Q35312833 | The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls |
| Q38174279 | The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems |
| Q38062033 | The impact of current and novel anti-diabetic therapies on cardiovascular risk |
| Q47261527 | The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. |
| Q42584383 | The influence of incretin mimetics on cardiovascular risk factors in diabetes |
| Q43140566 | The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. |
| Q37926558 | The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury |
| Q38023943 | The potential role of sphingolipid-mediated cell signaling in the interaction between hyperglycemia, acute myocardial infarction and heart failure |
| Q52718518 | The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin. |
| Q36193707 | The role of the Wnt signaling pathway in incretin hormone production and function |
| Q64999167 | The use of GLP-1 receptor agonists in hospitalised patients: an untapped potential. |
| Q36783865 | Therapy in the early stage: incretins |
| Q37804539 | Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications |
| Q54522495 | [Cardiovascular effects of incretin-based therapies]. |
| Q84219895 | [Diabetes and heart failure] |
| Q84219888 | [Incretins: do they exert cardiovascular effects?] |
Search more.